Kim Gibae, Lee Grim, Jarhad Dnyandev B, Gao Zhan-Guo, Kim Seung Woo, Joung Misuk, Jacobson Kenneth A, Jeong Lak Shin
Research Institute of Pharmaceutical Sciences, College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea.
Department of Chemistry, University of Texas at Austin, Austin, Texas 78712, United States.
ACS Med Chem Lett. 2025 Apr 2;16(5):880-886. doi: 10.1021/acsmedchemlett.5c00138. eCollection 2025 May 8.
Numerous adenosine receptor (AR) ligands have been synthesized over many years, but the development of 2,8-disubstituted nucleoside derivatives was limited due to the lack of efficient synthetic methods. Leveraging Pd catalyst-controlled regioselective coupling, we embarked on structure-activity relationship (SAR) analyses at the C8 position. Our SAR studies revealed that an aliphatic alkyne chain of specific length, such as 1-hexyne, at the C8 position is ideally suited for hAAR interaction. A computational docking study revealed that the π-π interaction between His95 and C8-aromatic alkyne could induce an active conformation of hAAR. Notably, compound demonstrated exceptional potency and selectivity at hAAR ( = 3.0 ± 0.5 nM), acting as the first 2,8-disubstituted nucleoside AAR partial agonist. It underscores the strategic importance of C8 position modifications in modulating AR activity and function, paving the way for novel therapeutic agents targeting AR-mediated diseases.
多年来已合成了许多腺苷受体(AR)配体,但由于缺乏有效的合成方法,2,8-二取代核苷衍生物的开发受到限制。利用钯催化剂控制的区域选择性偶联,我们开始在C8位置进行构效关系(SAR)分析。我们的SAR研究表明,C8位置特定长度的脂肪族炔烃链,如1-己炔,非常适合与人AAR相互作用。一项计算对接研究表明,His95与C8-芳族炔烃之间的π-π相互作用可诱导人AAR的活性构象。值得注意的是,化合物在人AAR上表现出非凡的效力和选择性(EC50 = 3.0 ± 0.5 nM),作为首个2,8-二取代核苷AAR部分激动剂。它强调了C8位置修饰在调节AR活性和功能方面的战略重要性,为靶向AR介导疾病的新型治疗药物铺平了道路。